Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
Evidence dashboardStudies since 2001Updated Jul 31, 2026

Thymosin Alpha-1Clinical Trials.

A source-linked view of every Thymosin Alpha-1 study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.

Total trials
63
Recruiting
12
Completed
22
Terminated
1
Results posted
2
Average enrollment
261
Countries
16
Highest phase
Phase 4

Largest indexed study

2,944 participants · NCT04320238 →

Developer / research origin

SciClone Pharmaceuticals

Evidence summary

Activity is not efficacy.

Thymosin Alpha-1 appears in 63 indexed studies: 12 recruiting, 22 completed and 2 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Thymosin Alpha-1 is safe or effective.

Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.

Development history

Trial timeline.

Evidence timeline

2001—2027

200120022002200220042005201320132013201520162016201720182020202020212021

Velocity

Thymosin Alpha-1 studies by start year

Study start year · indexed snapshot

8642020012001: 1 trials2002: 3 trials2003: 0 trials2004: 3 trials2005: 1 trials20062006: 0 trials2007: 1 trials2008: 1 trials2009: 2 trials2010: 0 trials20112011: 2 trials2012: 0 trials2013: 3 trials2014: 0 trials2015: 3 trials20162016: 8 trials2017: 2 trials2018: 2 trials2019: 0 trials2020: 3 trials20212021: 4 trials2022: 3 trials2023: 6 trials2024: 8 trials2025: 4 trials20262026: 2 trials20272027: 1 trials

Development

Trials by phase

Early Phase 11
Phase 17
Phase 231
Phase 38
Phase 410

Current studies

Recruiting or active

Completed studies

Finished records

Stopped studies

Withdrawn or terminated

Showing 6 of 21 studies
Showing 6 of 22 studies

Full study index

Search Thymosin Alpha-1 trials.

Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.

63 matching studies

Latest publications

Follow the paper trail.

PMID 34020252 ↗Graham JJ, Longhi MS, Heneghan MA. T helper cell immunity in pregnancy and influence on autoimmune disease progression. J Autoimmun. 2021 Jul;121:102651. doi: 10.1016/j.jaut.2021.102651. Epub 2021 May 18.Linked from NCT07675980PMID 33362999 ↗Dominari A, Hathaway Iii D, Pandav K, Matos W, Biswas S, Reddy G, Thevuthasan S, Khan MA, Mathew A, Makkar SS, Zaidi M, Fahem MMM, Beas R, Castaneda V, Paul T, Halpern J, Baralt D. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020 Dec 15;9(5):67-78. doi: 10.5501/wjv.v9.i5.67.Linked from NCT07675980PMID 8373526 ↗Kaufmann RA, Welch RA, Mutchnick MG. Low periconceptional maternal serum thymosin alpha 1 levels are associated with blighted pregnancies. Am J Reprod Immunol. 1993 Apr;29(3):171-5. doi: 10.1111/j.1600-0897.1993.tb00583.x.Linked from NCT07675980PMID 17600290 ↗Garaci E, Favalli C, Pica F, Sinibaldi Vallebona P, Palamara AT, Matteucci C, Pierimarchi P, Serafino A, Mastino A, Bistoni F, Romani L, Rasi G. Thymosin alpha 1: from bench to bedside. Ann N Y Acad Sci. 2007 Sep;1112:225-34. doi: 10.1196/annals.1415.044. Epub 2007 Jun 28.Linked from NCT07675980PMID 23045967 ↗Garaci E, Pica F, Serafino A, Balestrieri E, Matteucci C, Moroni G, Sorrentino R, Zonfrillo M, Pierimarchi P, Sinibaldi-Vallebona P. Thymosin alpha1 and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci. 2012 Oct;1269:26-33. doi: 10.1111/j.1749-6632.2012.06697.x.Linked from NCT07644897PMID 16741252 ↗Romani L, Bistoni F, Perruccio K, Montagnoli C, Gaziano R, Bozza S, Bonifazi P, Bistoni G, Rasi G, Velardi A, Fallarino F, Garaci E, Puccetti P. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006 Oct 1;108(7):2265-74. doi: 10.1182/blood-2006-02-004762. Epub 2006 Jun 1.Linked from NCT07644897PMID 20194853 ↗Maio M, Mackiewicz A, Testori A, Trefzer U, Ferraresi V, Jassem J, Garbe C, Lesimple T, Guillot B, Gascon P, Gilde K, Camerini R, Cognetti F; Thymosin Melanoma Investigation Group. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol. 2010 Apr 1;28(10):1780-7. doi: 10.1200/JCO.2009.25.5208. Epub 2010 Mar 1.Linked from NCT07644897PMID 10741392 ↗Giuliani C, Napolitano G, Mastino A, Di Vincenzo S, D'Agostini C, Grelli S, Bucci I, Singer DS, Kohn LD, Monaco F, Garaci E, Favalli C. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol. 2000 Mar;30(3):778-86. doi: 10.1002/1521-4141(200003)30:33.0.CO;2-I.Linked from NCT07644897

Related pages

Keep researching Thymosin Alpha-1.

Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.

Market comparisonThymosin Alpha-1 research listings →Lab reportsSearch the COA ledger →Research vendor recordAscension Peptides →Research vendor recordNura Peptide →Research vendor recordGlacier Aminos →Research vendor recordEZ Peptides →Source registrySearch ClinicalTrials.gov ↗